Tuning the potency and selectivity of ImmTAC molecules by affinity modulation
© The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Immunology..
T-cell-engaging bispecifics have great clinical potential for the treatment of cancer and infectious diseases. The binding affinity and kinetics of a bispecific molecule for both target and T-cell CD3 have substantial effects on potency and specificity, but the rules governing these relationships are not fully understood. Using immune mobilizing monoclonal TCRs against cancer (ImmTAC) molecules as a model, we explored the impact of altering affinity for target and CD3 on the potency and specificity of the redirected T-cell response. This class of bispecifics binds specific target peptides presented by human leukocyte antigen on the cell surface via an affinity-enhanced T-cell receptor and can redirect T-cell activation with an anti-CD3 effector moiety. The data reveal that combining a strong affinity TCR with an intermediate affinity anti-CD3 results in optimal T-cell activation, while strong affinity of both targeting and effector domains significantly reduces maximum cytokine release. Moreover, by optimizing the affinity of both parts of the molecule, it is possible to improve the selectivity. These results could be effectively modelled based on kinetic proofreading with limited signalling. This model explained the experimental observation that strong binding at both ends of the molecules leads to reduced activity, through very stable target-bispecific-effector complexes leading to CD3 entering a non-signalling dark state. These findings have important implications for the design of anti-CD3-based bispecifics with optimal biophysical parameters for both activity and specificity.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:215 |
|---|---|
| Enthalten in: |
Clinical and experimental immunology - 215(2024), 2 vom: 07. Feb., Seite 105-119 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Robertson, Ian B [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 08.02.2024 Date Revised 09.04.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/cei/uxad120 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364226978 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364226978 | ||
| 003 | DE-627 | ||
| 005 | 20240409232225.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cei/uxad120 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1370.xml |
| 035 | |a (DE-627)NLM364226978 | ||
| 035 | |a (NLM)37930865 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Robertson, Ian B |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Tuning the potency and selectivity of ImmTAC molecules by affinity modulation |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.02.2024 | ||
| 500 | |a Date Revised 09.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Immunology. | ||
| 520 | |a T-cell-engaging bispecifics have great clinical potential for the treatment of cancer and infectious diseases. The binding affinity and kinetics of a bispecific molecule for both target and T-cell CD3 have substantial effects on potency and specificity, but the rules governing these relationships are not fully understood. Using immune mobilizing monoclonal TCRs against cancer (ImmTAC) molecules as a model, we explored the impact of altering affinity for target and CD3 on the potency and specificity of the redirected T-cell response. This class of bispecifics binds specific target peptides presented by human leukocyte antigen on the cell surface via an affinity-enhanced T-cell receptor and can redirect T-cell activation with an anti-CD3 effector moiety. The data reveal that combining a strong affinity TCR with an intermediate affinity anti-CD3 results in optimal T-cell activation, while strong affinity of both targeting and effector domains significantly reduces maximum cytokine release. Moreover, by optimizing the affinity of both parts of the molecule, it is possible to improve the selectivity. These results could be effectively modelled based on kinetic proofreading with limited signalling. This model explained the experimental observation that strong binding at both ends of the molecules leads to reduced activity, through very stable target-bispecific-effector complexes leading to CD3 entering a non-signalling dark state. These findings have important implications for the design of anti-CD3-based bispecifics with optimal biophysical parameters for both activity and specificity | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a T-cell activation | |
| 650 | 4 | |a bispecific | |
| 650 | 4 | |a cluster of differentiation 3 | |
| 650 | 4 | |a cytokine release | |
| 650 | 4 | |a cytotoxicity | |
| 650 | 7 | |a Antibodies, Bispecific |2 NLM | |
| 650 | 7 | |a Receptors, Antigen, T-Cell |2 NLM | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 650 | 7 | |a CD3 Complex |2 NLM | |
| 700 | 1 | |a Mulvaney, Rachel |e verfasserin |4 aut | |
| 700 | 1 | |a Dieckmann, Nele |e verfasserin |4 aut | |
| 700 | 1 | |a Vantellini, Alessio |e verfasserin |4 aut | |
| 700 | 1 | |a Canestraro, Martina |e verfasserin |4 aut | |
| 700 | 1 | |a Amicarella, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a O'Dwyer, Ronan |e verfasserin |4 aut | |
| 700 | 1 | |a Cole, David K |e verfasserin |4 aut | |
| 700 | 1 | |a Harper, Stephen |e verfasserin |4 aut | |
| 700 | 1 | |a Dushek, Omer |e verfasserin |4 aut | |
| 700 | 1 | |a Kirk, Peter |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical and experimental immunology |d 1966 |g 215(2024), 2 vom: 07. Feb., Seite 105-119 |w (DE-627)NLM00001527X |x 1365-2249 |7 nnns |
| 773 | 1 | 8 | |g volume:215 |g year:2024 |g number:2 |g day:07 |g month:02 |g pages:105-119 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cei/uxad120 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 215 |j 2024 |e 2 |b 07 |c 02 |h 105-119 | ||